Over the past few years, a pack of sleek, marketing-savvy startups have sprouted up offering online prescriptions for drugs for common medical conditions. But even as they’ve touted their rapid growth, they’ve provided few details about their financials — which they’re entitled to do, as privately held companies.
That changed on Thursday, when San Francisco-based Hims & Hers, one of the leaders in the online pharmacy space, filed paperwork with the Securities and Exchange Commission to go public — shining light for the first time on the detailed financials of a business in an emerging sector that’s transformed the way many people get their medications.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Authors Reprints
